HemoBioTech Announces New Patent for Treating Acute Blood Loss

HemoBioTech (Pink Sheets:HMBT) announced today the issuance of a new patent US 7,759,306 B2, "Methods of Treating Acute Blood Loss." HemoBioTech has an exclusive worldwide license from Texas Tech University to commercialize the technology. The new patent continues to May 16, 2026.

The new patent involves HemoTech which induces the production of new red blood cells in the body. Uses for HemoTech could involve the treatment of acute blood loss and anemia in trauma, surgery, cancer, kidney disease and heart disease. The market for treatment of acute anemia is over $2 billion.

HemoTech also has the advantage of delivering oxygen to tissue in the body since it is composed of modified hemoglobin. The combination of delivering oxygen and inducing new red blood cells could be an advantage for treating trauma, elective surgery in third world countries plagued with a high incidence of HIV or Hepatitis contaminated blood and for use by the military and homeland security.

Read the rest of the story at Business Wire